Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Diuréticos y sobrecarga de volumen en la ERC temprana (DOCK)

2 de septiembre de 2026 actualizado por: VA Office of Research and Development

Asociación de diuréticos con cambios en el volumen extracelular, péptidos natriuréticos, síntomas y resultados cardiovasculares en la ERC

Almost 15% of Americans have chronic kidney disease (CKD), with an even higher rate in Veterans due to common risk factors such as high blood pressure and diabetes. People with CKD have a high risk of cardiovascular (CV) diseases, such as heart attacks, heart failure, and strokes. Extra fluid in the body, called volume overload, may lead to CV disease in people with CKD. It is unknown if volume overload develops in the earliest stages of CKD, when treating it with common, inexpensive medicines called diuretics may improve long-term CV outcomes. This study will lay important groundwork to answer this question in Veterans with early CKD by comparing two ways to measure volume overload and studying the change in common symptoms like fatigue and short-term CV function after treatment with diuretic medicines.

Descripción general del estudio

Descripción detallada

The investigators previously showed that brain natriuretic peptide (BNP) and N-terminal-pro-BNP (NT-pro-BNP), measures of ventricular stretch, are associated with death and cardiovascular (CV) outcomes in patients with chronic kidney disease (CKD) stages 1-3, and the investigators' preliminary pilot results suggest that these natriuretic peptides may correlate with objective measures of excess extracellular volume (ECV) and with symptoms common in CKD. The overarching objective is to determine if initiation of diuretic treatment or increase in dose is associated with changes in BNP and NT-pro-BNP, patient-reported symptom burden, and short-term hemodynamic parameters in patients with CKD stages 1-3 and elevated blood pressure, and whether these changes correlate with changes in ECV. The central hypothesis is that the change in ECV after starting or increasing diuretics in Veterans with stages 1-3 CKD is associated with changes in 1) natriuretic peptides, 2) patient-level factors, and 3) CV physiology.

The investigators will compare the changes in natriuretic peptides, symptoms, and CV parameters with the change in ECV after diuretic initiation or dose increase. The primary aim is to determine if initiation of diuretic treatment or increase in diuretic dose is associated with changes in natriuretic peptides. Secondary aims are to determine the effect of diuretic change on patient-reported symptom burden, and CV physiology.

This clinical trial will include 46 outpatients with CKD stages 1-3 and blood pressure >140/90 mmHg. At the first visit, the investigators will initiate or increase the dose of a thiazide or loop diuretic. Study measures other than echocardiogram will be repeated 4 weeks after the intervention to determine changes in these parameters. ECV will be measured by whole-body multifrequency bioimpedance spectroscopy (BIS), which is a validated, non-invasive, painless measure of ECV. Plasma BNP and NT-pro-BNP will be measured, and patient-reported fatigue, depression, and quality of life will be quantified using validated questionnaires. Hemodynamic parameters include blood pressure, pulse pressure, and total peripheral resistance index (TPRI) and cardiac index measured by Non-Invasive Hemodynamic Monitoring. A transthoracic echocardiogram will measure left ventricular mass index, valvular disease, and diastolic dysfunction.

Variables will be compared within participants between baseline and Visit 2 using paired Wilcoxon Signed Rank tests or paired Student's t tests, depending on variable distributions. Correlations between change in ECV/total body weight and all continuous outcome measures will be analyzed using Spearman or Pearson correlations, applying appropriate transformations. Linear regression analysis will control for clinically relevant variables. The relationship between ECV/total body weight and natriuretic peptides from both visits will be evaluated using a mixed effects model to account for the change in these measures between baseline and Visit 2.

Tipo de estudio

Intervencionista

Inscripción (Actual)

49

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Texas
      • Houston, Texas, Estados Unidos, 77030-4211
        • Michael E. DeBakey VA Medical Center, Houston, TX

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Male or female Veterans age 18 years or older. There will be no upper age limit.

  • The presence of CKD stages 1, 2, or 3, as defined below by Kidney Disease Improving Global Outcomes guidelines, for a period of at least 3 months.

    • Stage 1: eGFR 90 mL/min/1.73 m2 and spot urine albumin-to-creatinine ratio 30 mg/g.
    • Stage 2: eGFR 60-89 mL/min/1.73 m2 and spot urine albumin-to-creatinine ratio 30 mg/g.
    • Stage 3: eGFR 30-59 mL/min/1.73 m2.
  • Measured blood pressure either >140 mmHg systolic or >90 mmHg diastolic at the two most recent clinic visits.

  • Able to understand and sign informed consent after the nature of the study has been fully explained.

Exclusion Criteria:

  • Unable to understand or provide informed consent.
  • Unwilling or unable to participate in the protocol or comply with any of its components.
  • CKD stages 4-5, defined as eGFR <30 mL/min/1.73 m2.
  • Receiving chronic hemodialysis or peritoneal dialysis.
  • Recipient of a kidney transplant.
  • Serum potassium <3.5 mEq/L at baseline.
  • Known left ventricular ejection fraction <40% on visual estimate based on chart review of available echocardiogram data.
  • Known hepatic cirrhosis.
  • Major limb amputation.
  • Known pregnancy.
  • Presence of a pacemaker or defibrillator.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Diuretic augmentation

The participant's blood pressure medication regimen will be altered to initiate a thiazide-type or loop diuretic in those not already prescribed a diuretic, or to increase the dose if one is already prescribed.

The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in NT-pro-BNP
Periodo de tiempo: 4 weeks

Change in NT-pro-BNP from baseline to 4 weeks after intervention

4 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in BNP
Periodo de tiempo: 4 weeks

Change in BNP from baseline to 4 weeks after intervention

4 weeks
Change in FACIT-F score
Periodo de tiempo: 4 weeks

Change in fatigue as measured by FACIT-F score from baseline to 4 weeks after intervention

4 weeks
Change in QIDS-SR16
Periodo de tiempo: 4 weeks

Change in depression as measured by the QIDS-SR16 from baseline to 4 weeks after intervention

4 weeks
Change in KDQOL
Periodo de tiempo: 4 weeks

Change in quality of life as measured by the KDQOL from baseline to 4 weeks after intervention

4 weeks
Change in total peripheral resistance index
Periodo de tiempo: 4 weeks

Change in total peripheral resistance index from baseline to 4 weeks after intervention

4 weeks
Change in systolic blood pressure
Periodo de tiempo: 4 weeks

Change in systolic blood pressure from baseline to 4 weeks after intervention

4 weeks
Change in diastolic blood pressure
Periodo de tiempo: 4 weeks

Change in diastolic blood pressure from baseline to 4 weeks after intervention

4 weeks
Change in mean arterial pressure
Periodo de tiempo: 4 weeks

Change in mean arterial pressure from baseline to 4 weeks after intervention

4 weeks
Change in pulse pressure
Periodo de tiempo: 4 weeks

Change in pulse pressure from baseline to 4 weeks after intervention

4 weeks
Change in cardiac index
Periodo de tiempo: 4 weeks

Change in cardiac index from baseline to 4 weeks after intervention

4 weeks
Change in extracellular volume normalized/total body weight
Periodo de tiempo: 4 weeks

Change in extracellular volume normalized to total body weight from baseline to 4 weeks after intervention

4 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Lucile P Gregg, MD MS, Michael E. DeBakey VA Medical Center, Houston, TX

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de febrero de 2023

Finalización primaria (Actual)

2 de octubre de 2025

Finalización del estudio (Actual)

2 de octubre de 2025

Fechas de registro del estudio

Enviado por primera vez

1 de diciembre de 2021

Primero enviado que cumplió con los criterios de control de calidad

16 de diciembre de 2021

Publicado por primera vez (Actual)

29 de diciembre de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

21 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir